Abbott Q2 2026 Earnings Raise Profit Outlook
Abbott Q2 2026 earnings prompted a raise in adjusted EPS guidance and highlighted structural heart strength, shifting focus to second-half device demand.
KEY TAKEAWAYS
- Raised full-year adjusted EPS guidance to $5.45-$5.60 after Q2 results.
- Q2 adjusted EPS was $1.31 and reported sales grew 13.0% year over year.
- Strength in structural heart and electrophysiology devices underpinned the guidance lift.
HIGH POTENTIAL TRADES SENT DIRECTLY TO YOUR INBOX
Add your email to receive our free daily newsletter. No spam, unsubscribe anytime.
Abbott Laboratories (ABT) raised its full-year profit forecast after reporting stronger-than-expected demand for structural heart and electrophysiology devices in its Q2 2026 earnings, disclosed in a press release on July 16, 2026. The improved outlook reflects better second-half prospects for these key device portfolios.
Quarter Results and Guidance
Abbott reported Q2 sales growth of 13.0% on a reported basis and 4.8% on a comparable basis versus the year-earlier period. GAAP diluted earnings per share (EPS) were $0.53, while adjusted diluted EPS reached $1.31, exceeding consensus estimates and landing at the top of prior guidance. The company raised its full-year adjusted EPS guidance to a range of $5.45 to $5.60 and reaffirmed comparable sales growth guidance of 6.5% to 7.5%. Abbott returned $2.1 billion to shareholders during the quarter through dividends and share repurchases.
Device Strength and Strategic Drivers
Abbott attributed the guidance increase primarily to stronger-than-expected performance in its Medical Devices division, especially in structural heart and electrophysiology portfolios. These segments, which include transcatheter valves, left atrial appendage closure products, and cardiac rhythm management devices, are expected to sustain demand through the second half of 2026.
The Diagnostics segment also contributed to revenue growth, supported by core-lab diagnostics and the first full quarter of revenues from Exact Sciences’ oncology diagnostics business. Abbott completed the acquisition of Exact Sciences in Q1 2026, which had been expected to dilute full-year adjusted EPS by about $0.20 per share.
Regulatory developments have reduced legal risks for Abbott’s nutrition business. The U.S. Department of Justice closed its criminal investigation into the company’s infant-formula plant on June 28, 2026, though related civil litigation continues. These factors, combined with device momentum and the integration of Exact Sciences, shape the company’s updated results and outlook.
Investor focus will likely shift to the pace of device demand in the second half and the timing and scale of Exact Sciences’ integration as key factors influencing whether the raised profit forecast for 2026 holds.
